ArticleBMC pediatrics2025
Splenic sequestration crisis in children with sickle cell disease in the Eastern region of Saudi Arabia.
Article in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Blood Transfusion and ABO Blood Groups in Sickle Cell Disease.Medicina (Kaunas, Lithuania) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute splenic sequestration crisis (ASSC) is a potentially life-threatening complication of sickle cell disease (SCD). Previous studies have shown that patients who carry the African sickle gene haplotypes have more severe SCD than those with the Asian haplotype. In Saudi Arabia (SA), people living in the eastern region are known to carry the Asian haplotype, whereas patients in the southwestern (SW) region are more likely to carry the African haplotype. The aim of this study was to determine the prevalence and clinical features of ASSC among children with SCD who originated from both regions but were living in the same environment in the eastern region of that country.
methodsThis retrospective cohort study included 340 children with SCD who visited our hospital from 2010 to 2020. The collected clinical data of patients with ASSC were compared between two groups of patients: eastern and SW children.
resultsOver the study period, out of 340 children with SCD, 50 patients had ASSC, with a male/female ratio of 2.1:1. There were 38 children from the SW region and 12 from the eastern region. The overall prevalence of ASSC was 14.7%, with no significant difference between the two groups (p = .56). The SW group was diagnosed with SCD at a younger age than their eastern peers [median (IQR)]: 8.5 (6-11) vs. 30.5 (24-36) months; p < .001. The median (IQR) steady state hemoglobin (HB) level in the SW group was significantly lower than that in the eastern group [8 (7.5-9) vs. 9 (8-10) gm/dL]; p = .001]. During the first instance of episode of ASSC, there was a significant difference between the SW group and the eastern group in the following parameters [median (IQR)]: age [25 (12-48) v. 72 (39-134) months, p = .001], HB [5.1 (4.4-5.9) v. 6.1 (5.9-6.4) gm/dL, p = .01], splenic size on admission [5.5 (3-8) v. 8 (6-9.5) cm, p = .01], and splenic size upon discharge [3 (2-5) v. 5 (3.5-5.5) cm below the costal margin, p = .02]. The SW group had a significantly greater number of recurrences than did the eastern group [3.5 (2-6) v. 2 (1.5-2.5); p = .03].
conclusionsThe overall prevalence of ASSC among SCD children in the eastern region of SA was 14.7%, and there was no significant difference between the eastern and SW groups. Despite living in the same environment in the eastern region, children from southwestern SA experienced more severe ASSC manifestations than their eastern peers.
trial registrationNot.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.